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Background: HIV antiretroviral treatment [ART] failure increases morbidity and mortality. In Kenya, use 
of treatment supporter, HIV serostatus disclosure, and support groups are believed to reduce the risk of 
treatment failure by improving adherence.  
Methods: We conducted a case-control study to identify factors associated with clinical or immunologic 
indicators of treatment failures. Cases and controls were adult patients attending a semi-urban HIV clinic 
who initiated ART at least six months prior to the study. Cases were patients who had a] a decline in CD4 
count [below baseline or 30% from highest value since ART initiation] or b] unimproved CD4 counts or c] 
a World Health Organization [WHO] stage III or IV opportunistic infection. Controls did not meet either 
immunologic or clinical criteria for treatment failure.  Information was obtained through face-to-face 
interviews medical chart reviews. 
Results: We enrolled 52 cases and 104 controls. Twenty-eight [53%] cases and 71 [70%] controls were 
women, and median age was 44 years [range: 38-50 years] among cases and 43 years [range:  38-49 years] 
among controls. Discontinued ART for 2 weeks or more [adjusted odds ratio [AOR] 8.9, 95% confidence 
interval [CI] 1.4-57.4] and alcohol use [AOR 7.2, 95% CI 1.1-45.5] were found to significantly increase the 
risk of ART failure. Compared to men who discontinued ART for less than 2 weeks, women who 
discontinued ART for less than 2 weeks had reduced risk [AOR 0.4, 95% CI 0.2-0.9] while those who 
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discontinued for two weeks or more had a greater risk [AOR 12.97, 95% CI 1.5-111.8] of developing ART 
failure. Social support factors were not associated with treatment failure. 
Conclusions: Discontinuing ART and alcohol use were identified to be modifiable factors associated with 
clinical or immunologic criteria of ART failure. Interventions with proven efficacy at reducing alcohol use 
and increasing continuous ART should be implemented. 
Key words: Antiretroviral treatment failure, HIV, AIDS, adherence, alcohol, Kenya 
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Introduction 
HIV disease stands out as one of the most profound 
public health concerns in the world.  By end of 2012, 
there were an estimated 35.3 million HIV-infected 
adults and children, 25 million of whom were living 
in Sub Saharan Africa [1].  Kenya has been severely 
impacted by HIV.  In 2012, there were 1.2 million 
HIV-infected Kenyans aged 15-64 years, accounting 
for 5.6% of this population [2].  The Kenyan Ministry 
of Health is the main provider of antiretroviral 
therapy [ART] for the Kenyan HIV-infected 
population which has been available at no cost to 
treatment eligible persons since 2006. By end of 
2012, there were over 600,000 Kenyan adults living 
with HIV who were receiving ART [3]. 
ART has been shown to decrease HIV-related 
morbidity and mortality [4-5] and, by reducing 
circulating virus in treated persons, decrease sexual 
transmission of HIV [6-7]. However, to be effective, 
ART must be taken consistently. Poor adherence to 
ART can lead to the development of drug resistance 
and the need to change to what is often a more 
expensive and toxic regimen [8]. Transmission of 
drug resistant HIV has also been documented [9] 
which adversely impacts initial treatment.  
Adherence to ART is therefore important to the 
health of the HIV- infected individual and to the 
public as a whole. To increase adherence among 
those on ART and consequently minimize the need to 
change to second or third line regimen, the Kenya 
Ministry of Health recommends that patients receive 
education and counselling prior to initiating ART that 
includes information on the importance of adherence 
[10]. In addition, as part of the psychosocial support 
all patients are encouraged to identify a treatment 
supporter, to disclose their HIV status to family 
members and/or sexual partners, and to join peer 
support groups [10].  The use of psychosocial support 
for persons on ART has been recommended to 
patients because these factors have been shown to be 
positively related to the physical and mental well-
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being of persons with chronic diseases[11] and is a 
coping strategy used by people living with HIV[12].  
A number of interventions to increase ART 
adherence, including the use of a treatment supporter, 
have been tested and found to be efficacious in many, 
but not all settings,[13]. How these interventions 
translate from research settings into improved 
adherence and reduced treatment failure in standard 
care environments is less clear. We conducted a case-
control study to determine the association between 
socio-demographic, behavioral, and social support 
factors and ART failure among patients receiving 
ongoing care at Rift Valley Provincial General 




Study design, subjects and setting  
The study was conducted in May to July 2012 at the 
Rift Valley Provincial Hospital which is located in 
Nakuru County, Kenya. On average 90 to 120 HIV-
infected persons are managed at the HIV outpatient 
clinic each day.  During the study period, patients 
with a CD4 count of less than 350 cells/mm3, a World 
Health Organization [WHO] clinical stage III or IV 
or HIV, co-infection with tuberculosis or with 
hepatitis B virus,[10] were eligible for ART.  
Stabilized patients on ART were monitored clinically 
every two to three months and immunologically 
through CD4 counts measured every six months.  As 
per national policy, viral load testing is not routinely 
done but is instead limited to confirm the need to 
change regimens in patients identified to have clinical 
and/or immunological signs of ART failure,[10].   
The study population included patients aged 18 years 
and older at the time of data collection who had been 
enrolled at the HIV outpatient clinic and receiving 
ART for at least six months. A case was recruited if 
they had a decline in CD4 count [below baseline or 
30% from highest value since ART initiation], 
unimproved CD4 counts from baseline, or a WHO 
stage III or IV opportunistic illness. A control was 
recruited if all aforementioned signs were absent. 
Patients were excluded from the study if they did not 
meet the eligibility criteria, did not give consent, or 
were too sick to participate [as determined by the 
triage nurse]. 
A total of 156 study participants were recruited with 
two controls enrolled for every case. Sample size was 
calculated using the Fleiss formula [1981] and with 
assumptions made from a study conducted in an 
urban clinic in Uganda that investigated poor 
adherence as a predictor of ART failure [14-Gregory 
et al., 2007].  At the start of the data collection, the 
clinicians at the HIV outpatient clinic were re-trained 
on the criteria outlined in the national ART guidelines 
for identification and diagnosis of ART failure,[10].  
In addition they were instructed on the study 
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objectives, subject eligibility criteria and data 
collection methods.  The clinicians identified the 
patients who met any one of clinic-immunological 
criteria of ART failure as stipulated in the ART 
treatment guidelines,[10] and referred them to the 
study team who confirmed that the patients met at 
least one of the immunological or clinical criteria for 
ART failure.  For every case identified, the next two 
patients who were seen by the clinician and did not 
fit the case definition of ART failure were recruited 
as controls. If either cases or controls refused 
participation, the next eligible patient was recruited 
until the sample size was met. 
Measurements 
On enrolment into the study, a standard questionnaire 
was administered to each study participant that 
collected socio-demographic, behavioral, and social 
support factors thought to be associated with 
treatment failure. The medical records of participants 
were reviewed to obtain data on CD4 count at ART 
initiation, and the dates of clinic enrollment and ART 
initiation. 
Statistical analysis 
Crude odds ratios [OR] with 95% confidence 
intervals [CI] were used to measure differences 
between cases and controls. Stratified and 
multivariate analysis was done to assess for effect 
modification and confounding.  To evaluate for effect 
modification stratum specific OR were compared to 
assess if the range of associations was wide enough 
to be meaningful and represent normal sampling 
variation.  Variables that had a p value of 0.1 or less 
in the bivariate analysis were included in the 
multivariate logistic regression model.  In addition, 
interaction variables were created between the 
duration of non-adherence to ART and sex and these 
were also included in the model.  Step wise backward 
elimination method was used to develop the final 
model.  Statistical analysis was conducted using Epi 
Info version 3.5.1 [CDC, Atlanta, GA] and Stata 
[College Station, TX]. 
Ethical considerations 
Ethical clearance was obtained from the ethical 
review committees of the Kenya Medical Research 




A total of 156 patients; 52 cases and 104 controls 
were recruited into the study.  Cases and controls 
were demographically similar [Table 1].  Most of the 
study population were women, aged 35 to 44 years, 
had completed primary or secondary school, were 
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Table 1: Characteristics of patients who met and did not meet clinical or immunologic criteria for ART failure, 
Rift Valley Provincial General Hospital, Kenya, 2012.
Characteristic Total 
N [%] 
ART failure Crude OR 
[95% CI] 
P value 
Yes N [%] No N [%] 
Total study participants 156 [100] 52 [33] 104 [67]   
Demographic factors      
Sex      
      Male 59 [38] 25 [48] 34 [33] 1.9 [1.0–3.8] 0.09 
      Female 97 [62] 27 [52] 70 [67] Referent  
Age group [years]      
      25 - 34 17 [11] 8 [15] 9 [9] 2.4[0.8-7.2] 0.2 
      35 - 44 71 [46] 19 [37] 52 [50] Referent  
      45 - 54 50 [32] 16 [31] 34 [33] 1.3[0.6-2.8] 0.7 
      > 55 18 [12] 9 [17] 9 [9] 2.7[0.9-7.9] 0.1 
Highest education level      
     None 9 [6] 4 [8] 5 [5] 1.6[0.3-8.4] 0.4 
     Primary  65 [42] 23 [44] 42 [40] 1.1[0.5-2.4] 0.9 
     Secondary 67 [43] 22 [42] 45 [43] Referent  
     Post-secondary 15 [10] 3 [6] 12 [12] 0.5[0.1-2.2] 0.3 
Marital status      
Currently married 90 [58] 31 [60] 59 [57] Referent  
Separated/divorced 16 [10] 7 [13] 9 [9] 1.4[0.5-4.4] 0.7 
Never married/cohabited 14 [9] 4 [8] 10 [10] 0.8[0.2-2.9] 0.8 
Widowed 36 [23] 10 [19] 26 [25] 0.7[0.3-1.7] 0.6 
Employment status      
     Employed 42 [27] 16 [31] 26 [25] 1.4[0.7-3.1] 0.5 
     Irregular employment 86 [55] 26 [50] 60 [58] Referent  
     Unemployed 28 [18] 10 [19] 18 [17] 1.2[0.5-3.2] 0.8 
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The time from HIV diagnosis to entry into care and the time to ART initiation did not differ significantly between 
cases and controls [Table 2a,b].  
Table 2a: Care and treatment, behavioral, and social support factors associated with treatment failure, Rift Valley 
Provincial General Hospital, Kenya, 2012







Crude Odds Ratio 
[95%CI*] 
P value 
 N [%] N [%] N [%]   
Care and treatment factors      
Period between HIV 
diagnosis and enrolment into 
HIV clinic 
     
Less than 12 months 123[79] 44[85] 79[76] Referent  
12 months or more 33[21] 8 [15] 25[24] 1.7[0.7-4.2] 0.2 
Period between enrolment 
into HIV clinic and start of 
ART 
     
Less than 12 months 137[89] 44[85] 93[89] Referent  
12 months or more 19[11] 8[15] 11[11] 0.65[0.2-1.7] 0.4 
CD4 count at  ART initiation      
Less than or equal to 150 
cells/mm3 
72[54] 28[67] 44[48] 2.1[1.0-4.7] 0.07 
More than 150 cells/mm3 61[46] 14[33] 47[52] Referent  
Behavioral factors      
Longest duration off ART       
0 days 122[78] 34[65] 88[85] Referent  
1 – 14 days 15[10] 4[8] 11[10] 0.9[0.2-3.5] 0.6 
More than 14 days 19[12] 14[27] 5[5] 7.2[2.4-21.7] 0.0002 
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Table 2b: Care and treatment, behavioral, and social support factors associated with treatment failure, Rift Valley 
Provincial General Hospital, Kenya, 2012. 







Crude Odds Ratio 
[95%CI*] 
P value 
      
 N [%] N [%] N [%]   
Alcohol use in past three 
months 
     
Yes 14 [9] 9 [17] 5 [5] 4.1[1.2-16.5] 0.01 
No 142 [91] 43 [83] 99 [95] Referent  
History of use of substances 
other than alcohol while on 
ART 
     
Yes 11[7] 8 [15] 3 [3] 6.1[1.4-37] 0.007 
No 145 [93] 44 [85] 101 [97] Referent  
Social support factors      
Disclosure of HIV status      
Yes 127[81] 45[87] 82[79] Referent  
No 29[19] 7[13] 22[21] 1.7[0.7-4.3] 0.3 
      
Has a treatment supporter      
Yes 83 [53] 26 [50] 57 [55] 0.8[0.4-1.6] 0.7 
No 73 [47] 26 [50] 47 [45] Referent  
      
Member of a support group      
Yes 16 [10] 8 [16] 8 [8] 2.3[0.8-6.4] 0.2 
No 137 [90] 42 [84] 95 [92] Referent  
*Confidence interval 
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In the bivariate analysis we found four factors that 
were associated with increased risk for treatment 
failure: non-adherence to ART for two weeks or more 
[OR 7.2, 95% CI 2.4-21.7], alcohol consumption in 
the past three months [OR 4.1, 95% CI 1.2-16.5], and 
use of illicit substances other than alcohol [OR 1.4 
95% CI 1.4-37] [Table 2]. A CD4 count of 150 
cells/mm3at ART initiation was more frequent among 
patients failing treatment but the difference between 
the cases and controls was of borderline significance 
[p=0.07]. Though not shown in the table, patients 
failing ART had a lower median CD4 cell count at 
ART initiation than controls [104 cells/mm3and 154 
cells/mm3, respectively, p=0.05].  Having a treatment 
supporter, belonging to a support group or non-
disclosure of HIV status were not significantly 
associated with ART failure. 
In the multivariate analysis, having discontinued 
ART for 2 weeks or more and alcohol use were found 
to significantly increase the risk of ART failure 
[Table 3]. 
 
Table 3.Multivariate analysis of predictors of treatment failure. 
 
Significant interaction between sex and the duration 
of non-adherence was found. Compared to men who 
discontinued ART for less than 2 weeks, women who 
discontinued ART for less than 2 weeks had lower 
risk of developing failure while those who 
discontinued for more than 2 weeks had a greater risk 









Alcohol use in past three months 9 [17] 5[5] 7.2 1.1-45.5 
Discontinued ART for 2 weeks or more 14 [27] 5 [5] 8.9 1.4-57.4 
Discontinued ART period and sex     
Male and discontinued ART for less than 2 weeks 20[80] 30[88] Referent Referent 
Male and discontinued ART for 2 weeks or more 5[20] 4[12] 1.49 0.34-6.61 
Female and discontinued ART for less than 2 
weeks 
18[67] 69[99] 0.41 0.19-0.89 
Female and discontinued ART for 2 weeks or more 9[33] 1[1] 12.97 1.50-111.75 
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of developing ART failure.  Comparison between 
men who discontinued ART for less than 2 weeks and 
those that discontinued for more than 2 weeks 
indicated that the latter group had a greater risk of 




In an HIV clinic located in a referral hospital in semi-
urban part of Kenya, patients on ART were more 
likely to fail if they had a recent history of alcohol use 
or had discontinued ART for 2 weeks or more. The 
association between discontinuation of ART and 
clinical deterioration is expected and understood to 
be a direct effect on continued immune destruction in 
the absence of ART. In contrast, the association 
between alcohol and clinical or immunologic markers 
of treatment failure is likely to be an indirect effect 
most likely on compliance with treatment regimens. 
Previous studies have demonstrated an association 
between alcohol use and inadequate adherence,[15-
17].As such, to optimize adherence, and thereby 
improve clinical outcomes and reduce the risk of 
transmission of resistant strains, factors that directly 
and indirectly affect adherence must be addressed. 
Use of alcohol and other mood altering substances is 
not routinely ascertained in ART clinics but given its 
association with poor adherence, as well as other 
adverse health outcomes, health care providers in 
ART clinics in Kenya should routinely inquire about 
substance use as part of routine clinical monitoring.  
An unexpected finding was the modifying effect of 
sex on discontinuation of ART and treatment failure. 
Among subjects for whom the duration off ART was 
under 14 days most of whom had not missed any days 
of treatment] females were found to have a lower risk 
of developing ART failure compared to men. 
However, females who discontinued ART for more 
than 2 weeks were thirteen times more likely to 
develop failure as compared to men who had 
discontinued for less than 2 weeks. Relative to men 
who had missed ART for less than two weeks, men 
who missed ART for two weeks or more had slightly 
higher odds of treatment failure but this was not 
statistically significant. Although health behaviors 
have been shown to differ between men and women, 
the magnitude of increased risk among women who 
had discontinued treatment compared to men who 
had discontinued treatment merits further 
examination. 
In this study, participating in a support group, having 
a treatment supporter or history of having disclosed 
one’s status to someone were found to have no effect 
on ART failure. Functional social support that 
involves emotional and practical support has been 
shown to be more strongly associated with ART 
adherence than with structural support which 
involves how one lives and whether on is in a 
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relationship or not,[17].  In a study carried out in 
Tanzania,[18], to determine predictors of virological 
failure, history of disclosure of one’s HIV status was 
found to be protective. The first step in acquiring 
social support is disclosure of one’s HIV status. 
Although the majority of the participants in our study 
indicated that they had disclosed their status, it is 
possible that the disclosure in most cases was not 
made to persons who could provide support for HIV 
treatment. In addition, it is possible that persons who 
were aware of participants’ serostatus were not aware 
that they were receiving ART. As part of the 
interview, participants who acknowledged that they 
had a treatment supporter were asked to name that 
individual. It was noted that, patients usually gave the 
name of their next of kin, some of whom resided very 
far from the patients. As such, the degree of daily 
support for medication adherence was not likely to 
have been received from these supporters. Although 
belonging to a peer support group has been shown to 
be part of the forms of functional support,[19], we did 
not find that membership in a support group reduced 
the risk of ART failure. Though not captured 
systematically, the participants who had joined 
groups mentioned that the number of group members 
varied, meetings were scheduled infrequently and 
irregularly and lacked a structured format. 
Unfortunately our study only ascertained the 
presence of absence of these social support factors 
and did not systematically collect information on the 
quality or quantity of support received. Additional 
investigation that obtains detailed information on 
these factors and their relationship to adherence and 
treatment failure might identify a benefit of social 
support. Alternatively, it is possible that such factors, 
in the real world context in which our study was 
conducted, do not reduce the risk of treatment failure. 
 The findings from this study are subject to 
several limitations.  First, we had limited access to 
HIV viral load testing since the National Treatment 
Guidelines at the time prescribed targeted rather than 
routine viral load testing and therefore definition of 
treatment failure was done using clinical and 
immunologic criteria which has low positive 
predictive value,[20-24]. Thus, some of the cases 
may not have had high viral loads. This could explain 
why some factors did not differ between cases and 
controls.  Second, adherence to ART was measured 
through self-reports.  This would likely over-estimate 
adherence. This possibility was minimized because 
the study interview was administered by independent 
researchers rather than the routine clinical staff, a 
method shown to increase the reliability of self-
reported data,[25]. Third, patients who were too ill to 
participate were excluded and there is the very real 
possibility that such patients were failing therapy. As 
such, our findings might not be representative of 
patients with severe treatment failure but are likely to 
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provide important information among patients with 
early or mild symptoms of treatment failure.  
However, the strength of our study is that the data 
come from a typical clinic in a semi-urban area in 
Kenya and as such, present findings that are likely to 
be reflective in many similar settings where viral load 
testing is not routinely performed.  Based on our 
findings, we recommend that clinicians be 
encouraged to identify patients whose use of alcohol 
interferes with optimal health care behavior so that 
interventions to reduce alcohol use can be 
implemented. In the absence of additional 
information of a protective effect of social support 
against treatment failure, we recommend that proven 
strategies of increasing adherence, such as the use of 
text messaging as part of reminding the patients, 
continued counseling, family and psychological 
therapy,[26] be implemented in combination bearing 
in mind what will work best for a particular patient. 
Health care workers, people living with HIV and the 
public as a whole need to be educated on the 
importance of treatment adherence and its impact on 
reducing HIV-related morbidity and mortality and the 
opportunity for HIV-infected persons to lead healthy 
and productive lives. 
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